title: [Use of anti-aggregant drugs in primary and secondary cardiovascular prevention in diabetics in town and country in the León area].
abstract: OBJECTIVE
  To find how many diabetics should receive anti-aggregant treatment according to the recommendations made since 2001 by the American Diabetes Association (ADA), how many cardiovascular events could be avoided by 100 mg daily of acetylsalicylic acid (ASA), and the cost per event avoided by this measure.
  
  
  METHODS
  Transversal, descriptive, multi-centre study. SETTING. Primary care. 8 clinics in 5 health districts (3 rural, 1 semi-urban, 4 urban) in the León area. PARTICIPANTS. Diabetics aged 14 or over diagnosed through the ADA criteria since 1997. MAIN MEASUREMENTS. Audit of clinical records, collecting age and sex, the presence of the criteria of the ADA for anti-aggregation, the existence of established cardiovascular disease (CVD) and the anti-aggregant treatment patients receive. RESULTS. 544 diabetics. 97.2% (95% CI, 95.8%-98.6%) comply with anti-aggregation criteria. 101 had established CVD (18.6%; CI, 15.3%-21.9%); 77.2% received anti-aggregants (CI, 73.7%-80.7%).428 had no CVD and did have anti-aggregation criteria (78.7%; CI, 75.3%-82.1%); 9.3% (CI, 6.9%-11.7%) received treatment. CONCLUSIONS. There was basically little follow-up of the ADA anti-aggregation recommendations in primary prevention. Treatment of our diabetics with 100 mg/day of ASA would avoid 7.64 cardiovascular events in five years (CI, 5.56-9.72). The cost per cardiovascular event avoided was 6,625.37 euros (CI, 4821.60-8429.14 euros).
authors.affiliation: Médico de Familia. Centro de Salud Condesa. León. España.
authors.forename: J
authors.initials: J
authors.lastname: López De La Iglesia
authors.forename: S
authors.initials: S
authors.lastname: Escudero Alvarez
authors.forename: A M
authors.initials: AM
authors.lastname: González García
authors.forename: A
authors.initials: A
authors.lastname: Mencía Mieres
authors.forename: L E
authors.initials: LE
authors.lastname: García Andrés
authors.forename: B
authors.initials: B
authors.lastname: Morán Fernández
mesh_terms: D001241:Aspirin / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control; D003920:Diabetes Mellitus; D006801:Humans; D011320:Primary Health Care; D011322:Primary Prevention
chemical_list: D001241:Aspirin
vernacular_title: Empleo de antiagregantes en la prevención primaria y secundaria cardiovascular del diabético en el medio urbano y rural del área de León.